Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.72 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.52 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.52 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15893957 | 0.85 | BRD4 (0.71) | BRD4BRD9BRD7BRDT | |
| SCHEMBL16651898 | 0.84 | BRD4 (1.00) | BRD4BRD9BRD7BRDT | |
| Hydrochloric Acid SCHEMBL16650472 | 0.83 | BRD4 (0.97) | BRD4BRD9BRD7BRDT | |
| SCHEMBL6334276 | 0.81 | BRD4 (1.00) | BRD4BRD9BRD7BRDT | |
| SCHEMBL9919100 | 0.81 | BRD4 (0.73) | BRD4BRD9BRD7 | |
| SCHEMBL9922250 | 0.79 | BRD4 (0.54) | BRD4BRD9BRD7 | |
| SCHEMBL3103150 | 0.77 | BRD4 (0.72) | BRD4BRD9BRD7 | |
| SCHEMBL9922244 | 0.76 | BRD4 (0.51) | BRD4BRD9BRD7 | |
| SCHEMBL9922249 | 0.74 | BRD4 (0.49) | BRD4BRD9BRD7BRDT | |
| SCHEMBL9922701 | 0.74 | BRD4 (0.49) | BRD4BRD9BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | BRD4 3071/4885BRD9 1265/4885BRD7 3025/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | BRD4 3757/4885BRD9 1068/4885BRD7 3384/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | BRD4 3064/4885BRD9 1264/4885BRD7 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.